Document:

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 1 of 15

 

CONTRACT RESEARCH AGREEMENT

 

This agreement “Agreement”
is entered into on February 28th, 2012 by and between:

 

Crucell Holland B.V., a private
company with limited liability, with offices located at Archimedesweg 4, 2333 CN Leiden, the Netherlands, (“Crucell”),

 

and

 

Enumeral Biomedical Corp., a company organized under
the laws of Delaware, U.S.A., with offices located at 1450 Broadway, 24th Floor, New York, NY, 10018, U.S.A. (“Contractor”);

 

Each of Crucell and Contractor hereinafter
individually referred to as “Party” and collectively as “Parties”;

 

Whereas:

 

		Ø	Crucell is engaged in the business of
researching, developing, manufacturing, testing, marketing and selling vaccines and proteins to combat infectious diseases; 

		Ø	Crucell is the owner or licensee of certain
molecules, proteins and antibodies (“Materials”) and of associated information and know-how, including assays and intellectual
property rights thereto as further specified in Appendix I as attached to this Agreement;

		Ø	Contractor is an independent biotech company
providing a broad range of services for the research and development of products;

		Ø	Crucell wishes to hire Contractor, and
Contractor wishes to be hired by Crucell, to perform * screening services, antibody * services, and discovery of * services as
further specified in Appendix I as attached to this Agreement (“Research Project”);

		Ø	Crucell is willing to provide the Materials
and related Confidential Information to Contractor for such purposes;

		Ø	Crucell and Contractor recognize the need
to make suitable arrangements herein with respect to the use of the Materials and the use of the Results stemming from the Research
Project.

 

IT IS HEREBY AGREED as follows:

 

		1.	Statement of Work (SOW). The Research Project will be carried out in accordance with one or more specific detailed statements
of work that will be issued by Crucell, signed by both Parties and attached to this Agreement by written amendment in Appendix
1 (each a “Statement of Work” or “SOW”). Each SOW will also contain the financial terms and conditions,
including an invoicing schedule, for such SOW.

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 2 of 15

 

		2.	Provision of Information and Materials. Crucell shall make arrangements to provide Contractor with information and Materials
as necessary and at its disposal for the performance of the SOW.

 

		3.	Quality Agreement. The SOW will be performed in accordance with the terms of any quality agreement agreed between Parties,
as may be updated from time to time.

 

		4.	Materials and Results. The Materials are proprietary to Crucell. During the term of this Agreement, Contractor agrees
to maintain control over the Materials and all the results of the Research Project, including any materials, data, know-how and
other information resulting from the Research Project (“Results”), and further agrees not to disclose, give access
to or transfer the Materials and Results to persons not under its supervision and who do not need to receive or have access to
the Materials and Results for the performance of the Research Project, without the prior written approval of Crucell. Results shall
promptly be reported to Crucell during the performance of each SOW. Furthermore, the Materials shall only be used within the laboratories
of Contractor and by its employees for the purpose of performing the SOW and the Materials shall not be modified, altered, changed
and/or reconstructed other than as described in the SOW.

 

		5.	Intellectual Property. All right, title and interest to any intellectual property rights
with respect to the Results will vest in Crucell. Contractor will respond to reasonable inquiries of Crucell regarding the status
of each SOW and any inventions and intellectual property rights arising therefrom. If during the course and performance of the
SOW, inventions are conceived or reduced to practice, Contractor agrees that all right, title and interest in and to all such inventions,
shall vest in Crucell. Contractor will disclose promptly any inventions or improvements made
or conceived by Contractor either alone or jointly with others, in the course of or as a result of the performance of the Research
Project. Contractor shall assign its entire right, title and interest in and to any and all such inventions and improvements to
Crucell and execute such documents as may be required to file applications and to obtain patents in the name of Crucell or its
nominees, in any countries, covering such inventions or improvements. For the avoidance of doubt, the rights to any intellectual
property rights with respect to Results as set forth herein shall not include the rights to any underlying background technology,
materials or information that is proprietary to Contractor. Except as expressly set forth otherwise herein, nothing in this Agreement
grants either Party rights or a license to any patent, copyright, trademark, or other intellectual property rights of the other
Party. For the avoidance of doubt, nothing in this agreement expressly or otherwise provides for a license to Enumeral's technology:
Platform for quantitative single cell functional profiling (“Enumeral Technology”), nor any inventions, discoveries
or improvements to Enumeral’s Technology, whether patentable or not, which if practiced would constitute an infringement
of any Enumeral patent or other intellectual property rights, that arise from Enumeral’s application of the Enumeral Technology
in performance of the work as described in the Statements of Work. For clarity, such improvements to Enumeral’s technology,
including, but not limited to, the use of microengraving technology to measure, within * materials, the * with potential utility
in determining the presence or absence of disease processes will be owned solely by Enumeral provided that such improvements do
not claim or require the use of Crucell’s Material.

  

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 3 of 15

 

		6.	Deliverables. Deliverables from Contractor to Crucell shall be defined in each SOW and include all remaining Materials
and all Results. The invoicing schedule for each SOW will be based on these defined deliverables.

 

		7.	Compliance. Contractor shall use commercially reasonable efforts to perform each SOW within the term specified in the
respective SOW, and in accordance with the specifications, instructions, and guidelines in the SOW and this Agreement. The Parties
shall work together in good faith to ensure that each SOW clearly describes all methods, requirements, and obligations (other than
those set forth in this Agreement or a separate quality agreement). Contractor shall furthermore conduct its activities under this
Agreement in accordance with the highest ethical standards and best industry practices, including any voluntary codes of practice
applicable in the industry for the research, and all applicable laws and regulations, including the U.S. Foreign Corrupt Practices
Act. Contractor will comply with all applicable national and international laws, regulations and guidelines relating to protection
of the personal information of study subjects, including the European Commission Directive 95/46/EC as it relates to the protection
of the personal information, and the Standards for Privacy of Individually Identifiable Health Information (Privacy Rule) under
the United States Health Insurance Portability and Accountability Act of 1996 (HIPAA).

 

		8.	Payment. In consideration of Contractor’s performance of all activities set out in each SOW, Crucell will pay
Contractor the respective amounts specified in each such SOW. Parties will agree on the specifications that the Deliverables have
to meet for the fees to become due and payable, and include these in the SOW. If the Deliverables do not meet these specifications,
Contractor shall, at Crucell’s request, re-perform the SOW (or such portions thereof as may be reasonably required to be
re-performed), at Contractor’s cost, until the Deliverables are met. Payments will be made by Crucell within sixty (60) days
after receipt of a pertinent invoice from Contractor.

 

		9.	Use of Names. Neither Party will use the name of the other Party in relation to this Agreement in any advertising or
other form of publicity without the prior written consent of the other Party.

 

		10.	Confidentiality. Contractor will keep all information, whether in oral or written (electronic or paper) form or in the
form of a physical object or material disclosed or otherwise received in connection with the Research Project (“Confidential
Information”), and all Materials, and any derivatives and modifications thereof, and Results (together with Confidential
Information, collectively “Information”) confidential and will not use such Information or give access or disclose
the same to anyone other than those of its direct employees who need to receive such for the execution of the Research Project.
Contractor will make sure that confidentiality of Information is assured by a written confidentiality agreement with such employees
(which may include an employment agreement), the obligations of which are not less stringent than the obligations in this Agreement.
The confidentiality obligations shall not apply to the extent that Contractor is required to disclose Information by order or regulation
of a governmental agency or court of competent jurisdiction provided that Contractor gives Crucell prior written notice of such
disclosure and takes reasonable actions to avoid such disclosure or to minimize its extent, and to secure the confidentiality of
such disclosure.

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 4 of 15

 

Information shall not be deemed Information, to
the extent Contractor can demonstrate that:

 

		a.	the disclosed Information was at the time of such disclosure already in the public domain other than as a result of actions
of Contractor in violation hereof;

 

		b.	the disclosed Information was rightly known by Contractor (as shown by its written records) prior to the date of disclosure
by Crucell in connection with this Agreement, and was not acquired directly or indirectly from Crucell or from any other party
under an agreement of confidentiality to Crucell; or

 

		c.	the disclosed Information was received by Contractor (as shown by its written records) on an unrestricted basis from a source
unrelated to Crucell and not under a duty of confidentiality to Crucell.

 

		11.	Contractor’s R&W. Contractor represents and warrants that it has the experience, capability, and resources
necessary to perform the activities described in each SOW in a commercially reasonable manner and that it shall devote the necessary
personnel to perform the activities described in each SOW hereunder in a commercially reasonable manner.

 

		12.	No Crucell R&W’s. Contractor acknowledges that the Materials are experimental
in nature and are provided by Crucell for purposes of the Research Project only and “as is” with no warranties, express
or implied, including any warranty of merchantability, title, non-infringement or fitness for a particular purpose.

 

		13.	Liability and Indemnification.

 

		a.	Except for willful misconduct or gross negligence by Crucell, Crucell shall not be liable to Contractor
for any direct, consequential, incidental or indirect damages and/or loss arising from the use, handling or storage of the Materials
and the performance of the Research Project by Contractor, and Contractor shall hold Crucell harmless from, and indemnify Crucell
for, any such damage or claim relating thereto.

 

		b.	Except for willful misconduct or gross negligence by Contractor, Contractor shall not be liable
to Crucell for any direct, consequential, incidental or indirect damages and/or loss arising from the use of the Results by Crucell,
and Crucell shall hold Contractor harmless from, and indemnify Contractor for, any such damage or claim relating thereto.

 

		14.	Term and Termination.

 

		a.	This Agreement shall take effect on the date set out on the first page of this Agreement and will
terminate after the completion of the SOW’s under this Agreement.

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 5 of 15

 

		b.	Crucell may terminate this Agreement (i) with immediate effect in the event of insolvency or bankruptcy
of Contractor or (ii) at any time with thirty (30) days prior written notice. In the event of early termination, Contractor shall
be paid for all services performed and related expenses incurred in accordance with this Agreement until the date of notice of
termination is given or, with Crucell’s written approval, until the date of termination.

 

		c.	Either Party may terminate this Agreement upon the other Party’s breach of this Agreement,
provided that the terminating Party has given the defaulting Party no less than thirty (30) days’ prior written notice of
such breach and the defaulting Party has not cured such default by the end of the notice period.

 

		d.	Upon completion of the activities under the Research Project by Contractor or upon termination
of this Agreement, Contractor shall return to Crucell, or, if approved by Crucell in writing, destroy, all Information received
from Crucell hereunder and any tangible Materials, including any derivatives or modifications thereof received from Crucell hereunder
or generated as a result of the SOW performed by Contractor hereunder. Contractor shall have the right to retain one copy of all
documents to determine ongoing obligations under this Agreement, which documents shall be kept securely and in strict confidentiality
and only for such purpose.

 

		e.	Unless expressly provided to the contrary, the following provisions shall survive any termination
of this Agreement: Articles 5, 9, 10, 12 through 17, 19, 20 and 21.

 

		f.	Termination in accordance with this Article shall not prejudice any other remedy that a Party might
have.

 

		15.	Notice and Reports. All notices required by this Agreement shall be in writing. All notices
and reports shall be sent by fax or e-mail followed by registered or certified airmail to the Parties at the following addresses
or such other addresses as may be designated in writing by the respective Parties:

 

	To Crucell:	Crucell Holland B.V.
	 	Archimedesweg 4
	 	2333 CN Leiden
	 	The Netherlands
	 	Attn. *
	 	FAX:  +31-71-5199800
	 	 
	 	With a copy to the Legal Department at same address.
	 	 
	To Contractor:	Enumeral Biomedical Corp.
	 	1450 Broadway, 24th Floor
	 	New York, NY 10018
	 	Attn. Derek Brand, Director of Business Development
	 	Email: Derek@enumeral.com 

   

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 6 of 15

 

		16.	Relationship of the Parties. Contractor shall perform the Research Project as an independent
contractor and not as Crucell’s agent, representative or employee. Neither Party has any express or implied right or authority
to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any other contract,
agreement, or undertaking with any third party.

 

		17.	Assignability. Contractor’s duties and obligations assumed under this Agreement may
not be delegated to another party, and this Agreement may not be assigned or transferred (in whole or in part) by Contractor, without
the written consent of an authorized representative of Crucell. Crucell may assign this Agreement to any of its Affiliates or to
a purchaser of all or substantially all of Crucell’s assets relating to the subject matter of this Agreement. Crucell’s
Affiliate means with respect to this Agreement, any company, whether a corporation or other business entity, that is Controlling,
Controlled by or under common Control with Crucell; whereby “Control” means the direct or indirect ownership of more
than fifty percent (50%) of the equity interest in an entity, or the ability in fact to control the management decisions of such
entity. Crucell may assign this Agreement to an Affiliate, without the approval of Contractor.

 

		18.	Entire Agreement. This Agreement, including its Appendices, constitutes the entire agreement
of the Parties relating to the subject matter set out herein.

 

		19.	Amendment. This Agreement may not be changed, modified, amended, or supplemented except
by a written instrument duly signed by authorized representatives of both Parties hereto.

 

		20.	Choice of Law and Dispute Resolution. This Agreement shall be governed by and construed
under the laws of the Netherlands (without giving effect to the laws, rules or principles thereof regarding conflict of laws).
If any dispute arises out of or in connection with this Agreement, the Parties will themselves endeavor to settle such dispute
amicably. If the Parties fail to reach an amicable settlement of the dispute within a reasonable period of time, such dispute shall,
to the exclusion of all others, be referred to a competent federal court in New York, U.S.A., which court shall have exclusive
jurisdiction to settle any such disputes. The Parties agree that any judgment of a competent New York, U.S.A., court is enforceable
in any court having jurisdiction over the Parties.

 

		21.	Rules of Construction.

 

		a.	“Including”. The words “include”, “including” or “included”
are used to indicate that the matters listed are not a complete enumeration of all matters covered and should be read such as “including
but not limited to”.

		b.	Singular, Plural, Gender. Words denoting the singular, shall include the plural and vice
versa. Words denoting one gender shall include all others.

		c.	Severability. If any part of this Agreement shall be held invalid and/or unenforceable,
the remaining provisions of this Agreement shall nevertheless remain in full force and effect provided that such provisions will
permit the transaction contemplated herein to take place in substantially the same manner as originally contemplated by the Parties.

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 7 of 15

 

		d.	Translations. This Agreement has been written and executed in the English language. Any
translation into any other language shall not be an official version of this Agreement. In the event of any conflict in interpretation
between the English version and such translation of this Agreement, the English version shall prevail.

		e.	Waiver. The waiver by either Party of a breach of any provisions contained herein shall
be in writing and shall in no way be construed as a waiver of any prior or succeeding breach of such provision or the waiver of
the provision itself. No delay or omission on the part of either Party to exercise or avail itself of any right or remedy that
it has or may have hereunder shall operate as a waiver of any right or remedy.

 

AGREED and signed by:

 

	Crucell Holland B.V.	Enumeral Biomedical Corp.
	 	 
	/s/ Bart van Zijll Langhout	/s/ Arthur Tinkelenberg
	
        Name: Bart van Zijll Langhout

        Function: Managing Director
	
        Name: Arthur Tinkelenberg

        Function: President and CEO

	Date: 10/5/2012	Date: 4/16/2012

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 8 of 15

 

Appendix 1

 

STATEMENT OF WORK (SOW)

 

This Statement of Work (“SOW”) is made and entered
into as of March 29, 2012 (the “SOW Effective Date”) by and between Enumeral Biomedical Corp. (“Contractor”
or “Enumeral”) and Crucell Holland B.V. (“Crucell”).

 

This SOW is pursuant to, and incorporates the provisions of,
the Contract Research Agreement, dated February 28, 2012, by and between Contractor and Crucell (“Agreement”).

 

Under this SOW Parties agree as follows:

 

Research Project:

 

Background 

 

Overview

This SOW includes two projects with direct applications to the
development of vaccines and therapeutics *.

 

Project 1: Screening of *. Enumeral will identify
* that react with * antibodies and display favorable aqueous solubility.

 

Project 2: * analysis of * antibodies. Enumeral
will screen samples from *, along with a control group to identify the frequency and isotype of * (along with cell surface phenotype),
and retrieve any cells producing antibodies *.

 

Timelines Project 1:

 

Project 1: * Screening (see
pages 5-6)

Phase 1: Assay development *

Phase 2: Screen of Crucell *

 

Commercial conditions Project
1:

 

* Screening

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 9 of 15

 

Total amount for the services performed under Phase 1, including
FTE costs, equipment access, and necessary supplies and reagents to complete the specified work. The employees involved will include
*.

 

Total Amount: * will be paid by Crucell as follows:

 

		·	$50,000 (fifty thousand USD) will be paid by Crucell after demonstration
of the developed assay and completion of screening program for one of the three delivered * (estimated *) and receipt of the related
invoice by Crucell;

		·	$50,000 (fifty thousand USD) will be paid by Crucell after completion
of screening of remaining * (estimated *) and receipt of the related invoice by Crucell;

		·	* will be paid by Crucell after delivery of * (estimated *) and receipt
of the related invoice by Crucell.

 

All payments will be made by Crucell in accordance with the
payment schedule as set out above and within 60 (sixty) days after receipt of a pertinent invoice from Enumeral containing a specification
of the costs and a reference to Purchase Order number (to be supplied by Crucell after execution of this SOW).

 

As may be appropriate, development and commercial milestones
arising from future work requested by Crucell related to each of the aforementioned projects can be discussed at the conclusion
of the respective projects. Any additional services are subject to Article 19 of the Agreement.

 

Programs, Materials and requirements and Deliverables

 

The services includes specified reagents and materials developed
by Crucell (see Materials), along with specific technological expertise, materials, and instrumentation as provided by Enumeral.

 

Materials are defined as follows and will be provided by
Crucell:

		·	Project 1: *-Screening: Crucell will provide * expressing * molecules,
along with appropriate * and * antibodies for binding analyses, including various un-tagged and tagged versions, per previous conversations
between Enumeral and Crucell and described in more detail below.

 

Enumeral Materials:

		·	Devices & standard-reagents; including microwell arrays, cover-slides,
commercially-available capture and detection antibodies, and other elements necessary to carry out the work described.

		·	Enumeral will acquire * and from * controls for the “Pilot Phase”
of the * program.

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 10 of 15

 

Project Details:

 

Project 1:

 

Assay Development

Assay development will be carried out as the first step for
both programs; this will allow selection of the best reagents that will provide consistency across each program. Key factors include:

		·	Ensuring proper binding of captured * during the microengraving process;

		·	Selecting appropriate antibody reagents for either capture or detection
during the microengraving process and in-well cytometry.

 

Enumeral will discuss results for both the * and * assay development
processes with Crucell prior to initiating screening in either program. The decision to continue to the screening of * will be
made upon Crucell’s sole discretion. If Crucell decide not to continue the SOW shall be deemed to be terminated after completion
of the Assay Development under Project 1.

 

* Screening Program

 

Program Goal: To identify, * that (i) bind robustly to
* antibodies provided by Crucell and (ii) display favorable aqueous solubility. Enumeral’s technology will be utilized to
identify, from * Crucell *, soluble * that bind strongly to the provided * antibodies.

 

Crucell will supply *(or related *). In each case, * will be
interrogated using Enumeral’s Technology to simultaneously measure the binding of up to * different Crucell * antibodies
against soluble *microengraved from * assayed per well. Successful implementation of this screen would provide for the option to
extend the SOW to test *. Such decision to extend the SOW is upon Crucell’s sole discretion. Enumeral and Crucell will then
jointly determine conditions for selecting cells for retrieval. Cells will be retrieved during screening with Enumeral’s
Technology and transferred to 96 well plates. Cells will undergo RT-PCR and/or sequencing and the results will be provided to Crucell.

 

Deliverables

		·	Validated assay results presented to Crucell, which will demonstrate
the ability to identify soluble clones that bind strongly to * antibodies provided along with desired solubility. Both Parties
will decide on conditions for cell recovery during the second phase of testing (*).

		·	Frequency data and sequencing from recovered cells during screening
of * using the assay developed above (*).

 

Detailed Statement of Work: * Screening

Delivery of Materials:

		·	Crucell will provide Enumeral with *

		·	Crucell with also provide * antibody (and additional * antibodies
if desired) and * antibodies for the assay development phase.

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 11 of 15

 

		·	Crucell will provide Enumeral with * to undergo screening using the
developed assay.

 

Establishing Capture and Detection Conditions

		·	Limits of detection will be established using *. Pair—wise testing
of all combinations of antibodies as capture and detection reagents will be performed (as appropriate) to determine limits of detection
and optimal assay conditions for the different reagents.

		·	Example: *.

		·	Serial microengraving from the same * will be performed to establish
base-line binding of each of the Crucell antibodies to the soluble *. These tests will be run on * channels in parallel, which
effectively tests whether the * antibodies compete for *.

		·	Enumeral and Crucell will establish criteria for selecting cells for
retrieval during * screening.

 

Screen of *

		·	Each of the * will undergo screening using the microengraving assay
developed.

		·	Each * will undergo sufficient screening to assess “saturation”
and detection of best * e.g. based on rank-ordering of amount of * and affinity of binding by up to * antibodies provided by Crucell,
including *.

		·	Enumeral will recover cells that fit a retrieval profile decided upon
by Crucell and Enumeral (above), and corresponding * will be recovered and sequenced.

 

Timelines Project 2;

 

Project 2: * Program (see pages 7-9)

Phase 1: Assay Development (*)

Phase 2: Frequency Analysis – *

Phase 3: Screening and analysis of *

 

Commercial conditions Project 2:

 

* Program

Phase 1: Research fees cover FTE costs, equipment access, and
necessary supplies and reagents to complete the specified work. The employees involved will include *. The higher costs of this
phase reflect a greater level of FTE involvement, which will principally be led by the Director on the program.

 

Total Amount: * will be paid by Crucell as follows

		·	Phase 1-2”: * after delivery of frequency data pertaining to
* and receipt of the related invoice by Crucell.

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 12 of 15

 

In case Crucell has decided to continue to Phase
2 of Project 2, the Total Amount for the work under Phase 2 will be paid by Crucell as follows:

		·	Phase 3: * upon delivery of data including *

Phase 2: the costs include all FTE costs and increased instrument
time in order to process a high number of samples. A Research Associate will be primarily associated with data collection, while
a Director will oversee program progress and data analysis. Costs for the Patient Phase can be adjusted if there are substantial
changes to the statement of work after delivery of the Pilot Phase milestone (Discussed in more detail on Page 9) and after the
prior written approval of Crucell.

 

All payments will be made by Crucell in accordance with the
payment schedule as set out above and within 60 (sixty) days after receipt of a pertinent invoice from Enumeral containing a specification
of the costs and a reference to Purchase Order number (to be supplied by Crucell after execution of this SOW).

 

As may be appropriate, development and commercial milestones
arising from future work requested by Crucell related to each of the aforementioned projects can be discussed at the conclusion
of the respective projects. Any additional services are subject to Article 19 of the Agreement.

 

Program, Materials and requirements and Deliverables

The services includes specific reagents and materials developed
by Crucell (see Materials), along with specific technological expertise, materials, and instrumentation as provided by Enumeral.

		·	*: If suitable reagents are not commercially-available, Crucell will
provide * and appropriate tags or secondary detection reagents that will be appropriate for Enumeral’s assay development
strategies. Crucell will provide * for the “Patient Phase”)(Phase 2) of the project, which entails measuring *.

Enumeral Materials:

		·	Devices & standard reagents; includes microwell assays, cover
slides, commercially-available capture and detection antibodies, and other elements necessary to carry out the work described.

 

		·	Enumeral will acquire * and from * controls for the “Pilot Phase”
of the * program.

 

Project Details:

 

Project 2:

 

Assay Development

Assay development will be carried out as the first step for
Project 2; this will allow selection of the best reagents that will provide consistency across each program. Key factors include:

		·	Ensuring proper binding of captured * during the microengraving process;

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 13 of 15

 

		·	Selecting appropriate antibody reagents for either capture or detection
during the microengraving process and in well cytometry.

Enumeral will discuss results for the * assay development
processes with Crucell prior to initiating screening in either program.

 

Phase 1: * Analysis & Discovery of * Antibodies

 

Program Goal:  To determine the * and to recover and
sequence antibodies that *. The program will include two phases:

 

* Analysis (“Pilot Phase”). Enumeral will
obtain * and controls. Samples will be screened using Enumeral’s technology to determine *.

 

* will be characterized with respect to antibody specificity
to the * described above as well as *. Cell surface markers will be assessed using in well cytometry to identify common * markers
based on *.

 

Pilot Phase Deliverables

		·	Phase I: Assay developed to demonstrate binding to *. Data
demonstrating binding to the provided * will be presented, along with data showing that the assay is feasible for measurements
on *

		·	Phase II: Assessment of *. Data identifying the frequency
of antibodies binding * as well as * will be presented from *

 

Assessment Point: Crucell and Enumeral will
discuss results of pilot phase in order to make any recommended changes in the scope of work for the “Patient Phase”
of the program. Any such decision to continue or to amend the Project shall be made by Crucell upon its discretion.

 

Identification and Recovery of * (“Patient Phase”).
* will be provided by Crucell and screened to identify cells secreting antibodies *. Cells of interest will be retrieved and
the * of each cell sequenced. * analysis will first be processed to enrich for * populations, either by Crucell or Enumeral as
appropriate. Information on * is provided in Appendix 1.

 

Patient Phase Deliverable

		·	Data identifying the * antibodies, along with conserved sequences
and other elements of the antibody repertoire analysis from * will be presented. Sequences from antibodies * will be provided.
*

 

Detailed statement of work: *

 

Delivery of Materials:

		·	Crucell will provide Enumeral with *, and additional reagents specific
to the detection of said antibodies as deemed appropriate by Enumeral and Crucell.

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 14 of 15

 

		·	Crucell will provide Enumeral with * samples the final numbers and
respective inclusion criteria will be determined at the conclusion of the “Pilot Phase”. The current estimate is that
samples will comprise *.

 

Establishing Capture and Detection Conditions:

		·	* will be isolated from * (see Appendix 1 for details on *)

		·	Different activation conditions, including a comparison of “resting”
and activated will be compared to determine baseline and stimulated * events.

		·	Using * as a capture antibody, all * will be microengraved from *

		·	Cells will be arrayed in Enumeral devices the following analyses will
be performed to validate and characterize detection antibodies and cell surface marker reagents (including *:

		·	Detection of * antibodies will be performed using * antibodies
to validate best conditions for measuring baseline * events in the both resting and activated populations. This will allow characterization
of detection reagents and determination of appropriate sample sizes for screening patient samples.

		·	In well cytometry will be performed to determine cell surface
markers of highest interest. A specific set of markers will be chosen following correlation of * and cell population patterns (e.g.
* antibodies).

 

		·	Deliverable: Data demonstrating binding to provided * will
be presented, along with data showing that the assay is feasible for measurements on * samples, e.g. *.

 

Analysis of *:

		·	Enumeral will obtain * and controls *. Samples will be frozen and
stored appropriately. Samples will undergo enrichment as described above based on discussions between Enumeral and Crucell.

		·	Samples will be screened employing the assay conditions developed
above; screens will be performed under activated and unactivated (“resting”) conditions

		·	*. Cell surface markers will be enumerated to determine *.

		·	Cell retrieval conditions will be discussed between Crucell and Enumeral.
Cells secreting antibodies * will be retrieved using Enumeral’s specialized instrumentation and transferred to 96 well plates
for subsequent RT-PCR and sequencing.

		·	Deliverable: Data identifying the frequency of antibodies *
as well as * will be presented.

 

Assessment point: Results of the pilot phase
will be discussed to determine the appropriate structure for the Patient Phase and serve as a “go/no-go” decision point
for the program. Criteria for progressing to Patient Phase should include * antibodies. The decision to continue to the Patient
Phase will be made by Crucell upon its sole discretion. In case Crucell decided not to continue to the Patient Phase this SOW and
the Agreement shall be deemed to be terminated.

 

    	 

    	 

    

  

Agreement Contract Research

Crucell Holland B.V. – Contractor

Page 15 of 15

 

Phase 3: “Patient Phase: Screening of
patient samples Analysis of *

		·	Samples provided by Crucell will be processed and screened employing
assay conditions as above or modified per discussions at the conclusion of pilot phase.

		·	*. As above, cell surface markers will be enumerated to determine
marker dependent subsets that are also * antibody secreting cells.

		·	Cells secreting antibodies * will be retrieved using Enumeral’s
specialized instrumentation and transferred to 96 well plates for RT-PCR and sequencing. Retrieval criteria will be as above or
modified per discussions after Pilot Phase.

 

		·	Deliverable: Data identifying * will be provided.

 

Agreed and signed by:

 

	Crucell Holland B.V.	Enumeral Biomedical Corp.
	/s/ Bart van Zijll Langhout	/s/ Arthur Tinkelenberg
	Name: Bart van Zijll Langhout	Name: Arthur Tinkelenberg
	Function: Managing Director	Function: President and CEO
	Date: 11-05-2012	Date: 4/16/2012Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

MASTER SERVICE PROVIDER AGREEMENT

 

THIS AGREEMENT (the
“Agreement”) is made as of the 14th day of March, 2012 (“Effective Date”), by and between
Anthrogenesis Corporation, a New Jersey Corporation, doing business as Celgene Cellular Therapeutics (a wholly owned subsidiary
of Celgene Corporation) having its principal place of business at 33 Technology Drive, 2nd Floor, Warren, NJ 07059 (together
with its affiliates hereinafter collectively referred to as “CCT”) and Enumeral Biomedical Corporation, having
a place of business at 1450 Broadway, 24th Floor, New York, NY 10018 (hereinafter called “Service Provider”).

 

In consideration of
the mutual promises contained herein, the parties hereby mutually agree as follows:

 

1.   Appointment

 

Service Provider will
perform the services (the “Services”) described in the attached Exhibit(s), made fully a part hereof, according to
the timeframes and schedules listed in said Exhibit(s). In the event that the parties hereto shall reach agreement with respect
to the provision of additional services hereunder, such services shall be set forth in writing and attached hereto as additional
Exhibit(s), which Exhibit(s) shall be made fully a part hereof, and such services shall be deemed to be Services hereunder. No
such additional services shall be approved without first being reduced to a writing, which is executed by the parties hereto. To
the extent that terms contained in Exhibit(s) conflict with this Agreement, the terms and conditions of this Agreement will control.
Service Provider shall advise CCT of the names and provide CCT with the resume(s) of personnel prior to assigning them to perform
the Services if requested by CCT. CCT reserves the right, at its sole discretion, to reject any personnel.

 

2.   Compensation

 

In consideration for
Service Provider’s satisfactory performance of the Services, CCT shall pay Service Provider a fee in the amount and on the
terms specified in Exhibit(s) attached hereto. Invoices must reference the appropriate purchase order number and sent to the attention
of Accounts Payable, Celgene Cellular Therapeutics, 7 Powder Horn Drive, Warren, NJ 07059.

 

CCT shall pay the amount
of each invoice received from Service Provider within forty-five (45) days of receipt by CCT unless CCT has notified Service Provider
within such forty-five (45) day period that it disputes any particular invoiced item(s), which dispute the parties shall attempt
in good faith to resolve. Because of the difficulty in substantiating the validity of claims for payment increases with time, CCT
reserves the right to decline to pay on invoices more than ninety (90) days after an expense has been incurred. In no event will
CCT pay on invoices submitted more than one hundred eighty (180) days after an expense has been incurred.

 

    	Enumeral Biomedical CCT MSPA 2.17.12 rao (28651)	1

    	 

    

 

3.   Confidentiality

 

“Confidential
Information” shall, for the purpose of this Agreement, mean all information in any form, tangible or intangible, which may
be disclosed, or has been disclosed by CCT to Service Provider in writing, orally or by observation which is nonpublic, proprietary,
a trade secret, or confidential in nature and all of the information obtained from CCT or generated by Service Provider during
the course of its work for CCT. Service Provider agrees to hold in trust and confidence all Confidential Information. Service Provider
further agrees that it shall not disclose all or any part of such Confidential Information to any third party or make any use thereof
(except to perform the Services pursuant to the provisions of this Agreement), or publish or present any work which in whole or
in part uses or includes Confidential Information, without the prior written consent of CCT. Service Provider agrees to restrict
access to all Confidential Information to only such limited group of its authorized employees, who require such information in
connection with the performance of Services under this Agreement. Such authorized employees shall be under confidentiality obligations
at least as restrictive as set out in this Agreement. It is understood, however, that this restriction shall not apply to information
which Service Provider can demonstrate by its competent written records predating disclosure under this Agreement (i) was known
to it prior to the relationship between CCT and Service Provider, (ii) was lawfully revealed to Service Provider by a third party
which has the legal right to disclose such information, or (iii) is or becomes part of the public domain through no fault of Service
Provider. Service Provider shall return to CCT or destroy all Confidential Information in tangible form (including all copies,
extras or derivatives thereof in any medium) within thirty (30) days after the termination or expiration of this Agreement, or
upon request from CCT, whichever comes first, except that Service Provider may keep one (1) archival copy of such information in
its legal files solely for the purpose of monitoring compliance under this Agreement.

 

4.   Intellectual Property

 

4.1   Work for Hire

 

The parties expressly
agree that all work performed under this Agreement is a work made for hire as defined under 17 USC Section 101. All communications,
materials, concepts and plans developed by Service Provider which are or have been made, conceived or written by Service Provider
or its employees and which are based upon Services performed by Service Provider for CCT shall belong exclusively to CCT, including,
without limitation, all rights to obtain copyrights therein. In cases where an original work or a copy of an original work cannot
be assigned to and owned by CCT, CCT shall be notified by Service Provider, and Service Provider shall obtain rights of use in
CCT’s favor, as CCT may require. All communications, materials and artwork provided by CCT shall also remain the property
of CCT, including, without limitation, any copyrights or other intellectual property rights therein.

 

4.2   Assignment of Intellectual Property

 

Service Provider hereby
assigns to CCT all intellectual property, including, but not limited to, all patents, patent applications, copyrights, discoveries
and inventions, whether patentable or not, conceived or reduced to practice by Service Provider or its employees, agents or consultants,
alone or jointly with others, during the term of this Agreement, which intellectual property either (i) based upon any information
received from CCT or (ii) directly arising from the Services provided by Service Provider to CCT hereunder (“Intellectual
Property”). Service Provider agrees to disclose promptly and fully all Intellectual Property and to assist, and cause its
employees, agents and consultants to assist, CCT in every reasonable way, at CCT’s expense, to protect the rights of CCT
or any affiliate in the Intellectual Property, including, without limitation, to obtain patents and copyrights thereon in any and
all countries.

 

4.3   Background Technology

 

Notwithstanding the
foregoing, nothing in this Agreement expressly or otherwise provides for a license to Celgene of Service Provider’s pre-existing
technology, or any inventions, discoveries or improvements to Service Provider’s pre-existing technology which in no way
incorporates, references or utilizes any Celgene Confidential Information (together, “Improvements”), whether patentable
or not. For clarity, Improvements will be owned solely by Service Provider including, but not limited to, use of Service Provider’s
technology to measure from patient-derived materials, the single cell secretion of certain proteins with potential utility in determining
the presence or absence of disease processes.

 

5.   Term and Termination

 

This Agreement shall
be effective as of the Effective Date and shall remain in full effect for three (3) years from the Effective Date, unless terminated
in accordance with the terms below and may be renewed by mutual consent of Service Provider and CCT for such additional period
as the parties may agree upon; provided, however, if an Exhibit for Services is executed by the parties prior to the expiration
or termination of this Agreement and the Services under the Exhibit have not been completed prior to the expiration or termination
of the Agreement, then the term of this Agreement shall be automatically extended to expire on the earlier of (a) the completion
of the Services under the Exhibit, or (b) the termination by the parties of such Exhibit in accordance with Section 5(a) or 5(b)
below:

 

    	Enumeral Biomedical CCT MSPA 2.17.12 rao (28651)	2

    	 

    

 

		a.	CCT may:

 

(i) terminate
this Agreement or any Exhibit, at any time upon thirty (30) days written notice to Service Provider;

 

(ii) terminate
this Agreement immediately, in the event of the filing of a petition in voluntary bankruptcy or an assignment for the benefit of
creditors by Service Provider, or upon other action taken or suffered, voluntarily or involuntarily, under any federal or state
law for the benefit of debtors by Service Provider, except for the filing of a petition in involuntary bankruptcy against Service
Provider which is dismissed within thirty (30) days thereafter;

 

(iii) give
notice of the immediate termination of this Agreement in the event Service Provider shall materially default in the performance
of any duty or obligation imposed upon it by this Agreement and such default shall continue for a period of thirty (30) days after
written notice thereof has been given to Service Provider by CCT.

 

		b.	Service Provider may:

 

(i) terminate
this Agreement in the event CCT shall materially default in the performance of any duty or obligation imposed upon it by this Agreement
and such default shall continue for a period of thirty (30) days after written notice thereof has been given to CCT by Service
Provider.

 

Termination or expiration of the term hereof
shall not relieve Service Provider of the obligations imposed upon Service Provider, as set forth in paragraph 16.5. In the event
of termination by CCT for any reason other than Service Provider’s breach of the terms of this Agreement, Service Provider
shall be reimbursed for costs incurred directly in the performance of the Services prior to the date of the notice of termination,
and for all reasonable non-cancelable commitments incurred directly in the performance of the Services and outstanding as of that
date, provided that Service Provider uses its best efforts to mitigate same.

 

6.   Independent Contractor

 

The relationship of
Service Provider to CCT is that of an independent contractor and nothing herein shall be construed as creating any other such relationship.
Service Provider may adopt such arrangements as it may desire with regard to the details of the Services performed hereunder, the
hours during which the Services are to be provided, and the place or places where the Services are to be furnished, provided that
such details, hours and places shall be consistent with the proper accomplishment of the Services, and provided further that the
Services shall be performed in a manner calculated to attain the most satisfactory results for CCT. CCT and Service Provider acknowledge
and agree that the personnel employed by Service Provider in performing the Services shall remain at all times employees of Service
Provider, and Service Provider shall remain solely liable for all aspects of the employment of such persons including, recruitment,
termination, training, promotion, compensation, benefits, F.I.C.A., payroll taxes and all other deductions or payments to be made
by employers for or on behalf of employees. Service Provider shall not be, and shall not represent itself, or any of its employees,
officers, directors, representatives, agents or contractors to anyone as an employee of CCT, or as being entitled to any employment
rights or benefits from CCT.

 

    	Enumeral Biomedical CCT MSPA 2.17.12 rao (28651)	3

    	 

    

 

7.   Compliance

 

In the event Service
Provider is to perform any of the Services on CCT’s premises, Service Provider agrees that it shall comply with the applicable
safety rules and regulations of the particular location where the Services are to be performed, and CCT agrees that said safety
rules and regulations shall be made available to Service Provider before the commencement of performance of any such Service.

 

In the event Service
Provider receives notice of an adverse event in error from a third party, Service Provider will inform Celgene’s Drug Safety
Group within twenty-four (24) hours of receiving the notice, via Global Drug Safety Department, 86 Morris Avenue, Summit, NJ 07901,
phone: 800-640-7854; fax 908-673-9115/9154. The Service Provider shall collect from the reporter and provide to Celgene the following
minimum information: name, credentials, address, telephone and fax number of the reporter of the adverse event.

 

8.   Audit

 

8.1  During the term
of this Agreement and for two (2) years after its expiration or termination, CCT shall have the right to audit and inspect all
documentation related to the Services, including any financial records of Service Provider associated with this Agreement or any
Exhibit under this Agreement. Service Provider will make available all such documentation upon request for inspection, copying,
review and audit at reasonable times by representatives of CCT or any regulatory agencies. Such records may include, without limitation,
invoice records, invoices from third parties, contracts with third parties and payments relating to this Agreement. To the extent
such records are not separable from other customer records, Service Provider will give reasonable access to the records to an independent
auditor selected by CCT, who will audit the records and may disclose the results of the audit only to the extent it relates to
this Agreement. In no event shall other customer information be disclosed to CCT.

 

8.2   CCT will have the
right, but not the obligation, to independently visit Service Provider or any sites where the Services are performed to review
performance of Services herein. In the event CCT intends to undertake such visits, CCT will provide reasonable notification to
Services Provider, and Service Provider will provide assistance and cooperation.

 

8.3   Service Provider
agrees to take reasonable steps that are requested by CCT as a result of an audit to cure deficiencies in all documentation related
to the Services. Service Provider will retain copies of all documentation related to the Services, in conformance with applicable
national and local regulations and as specified by CCT. Service Provider agrees to advise CCT of any regulatory inspection and
to provide CCT with a copy of any inspection report. Any response to a regulatory agency will be subject to approval by CCT prior
to issuance. Such approval will not be unreasonable withheld.

 

9.   Indemnification

 

9.1   Indemnification
by Service Provider

 

Service Provider shall
indemnify, defend and hold harmless CCT and its officers, directors, employees and agents from and against all claims, causes of
action, suits, damages and costs arising out of, resulting from, or otherwise in respect of, the negligent acts, or willful misconduct
of Service Provider or its officers, directors, employees or agents pertaining to the activities to be carried out pursuant to
Service Provider’s obligations under this Agreement; provided, however, that Service Provider shall not hold CCT harmless
from claims to the extent arising out of the negligence or willful misconduct of CCT or its officers, directors, employees or agents.

 

9.2   Indemnification
by CCT

 

CCT shall indemnify,
defend and hold harmless Service Provider and its officers, directors, employees and agents from and against all claims, causes
of action, suits, damages and costs arising out of, resulting from, the negligent acts or willful misconduct of CCT or its officers,
directors, employees or agents pertaining to the activities to be carried out pursuant to this Agreement; provided, however, that
CCT shall not hold Service Provider harmless from claims to the extent arising out of the negligence or willful misconduct of Service
Provider or its officers, directors, employees or agents.

 

    	Enumeral Biomedical CCT MSPA 2.17.12 rao (28651)	4

    	 

    

 

10.   Equal Opportunity

 

Service Provider acknowledges
that it understands that CCT is an Equal Opportunity Employer and Service Provider warrants that Service Provider complies with
the Fair Labor Standard Act of 1938, as amended. Service Provider agrees that, if this Agreement is construed to be a subcontract
within the meaning of the Rules and Regulations approved by the United States Secretary of Labor pursuant to Executive Order 11246,
as amended, the Vietnam Era Veterans Readjustment Act of 1974, as amended, or the Rehabilitation Act of 1973, as amended, or of
the regulations issued pursuant to Executive Order 11625, the provisions of those regulations as well as the Equal Opportunity
and Nondiscrimination provision of Section 202 of Executive Order 11246 shall be incorporated herein by reference and shall be
binding upon Service Provider as part of this Agreement.

 

11.   Insurance

 

Commencing with the
performance of Services hereunder, Service Provider shall during the term of Service Provider’s obligations under Section
9 hereof, maintain insurance of the type and minimum coverage indicated below. The term of coverage shall be evidenced by certificates
of insurance to be furnished at CCT’s request.

 

	Type	 	Minimum Limits
	Worker’s Compensation	 	Statutory
	Employer’s Liability	 	$100,000
	General Liability	 	
        $1,000,000

        (Combined single limit)

	Automobile – any auto	 	
        $1,000,000

        (Combined single limit)

 

12.   Service Provider’s Warranties;
Conflicts of Interest

 

12.1   No Conflict of
Interest or FDA Debarment

 

Service Provider represents
and warrants that: (i) it has no obligations to any third party which (a) will in any way limit or restrict its ability to perform
Services for CCT hereunder or (b) conflict with the rights granted to CCT hereunder, (ii) it shall not disclose to CCT, nor make
any use of in the performance of Services hereunder any trade secrets or confidential or proprietary information of any third party
without the consent of such third party, and (iii) it has not been debarred or suspended by the FDA from providing services to
a company that has a pending or approved drug product application.

 

12.2   Requirement to
Advise of Future Conflicts

 

Service Provider further
warrants and affirms that it shall advise CCT of any relationship described in Section 12.1(i) that might arise during the term
of this Agreement. In such event, CCT shall have the option to immediately terminate this Agreement without further liability to
Service Provider other than the obligations to pay for Services actually rendered as of the date of termination.

 

12.3   Professional Standards

 

Service Provider warrants
that (i) it possesses the necessary expertise to perform the Services hereunder consistent with the highest professional standards
of the industry, and (ii) the Services will be performed in a professional and workmanlike manner consistent with the highest professional
standards of the industry. Service Provider shall re-perform any Services not in compliance with this warranty brought to its attention
within a reasonable time after those Services are performed.

 

    	Enumeral Biomedical CCT MSPA 2.17.12 rao (28651)	5

    	 

    

 

13.    Tax Reporting and Payment

 

Any tax or other governmental
charges that apply to this Agreement or to the compensation payable to Service Provider hereunder are conclusively presumed to
be included in such compensation and accordingly, any such tax or governmental charge shall not be added to any invoice submitted
by Service Provider. CCT is not responsible for payment of any employment, self-employment, or withholding taxes imposed as a result
of the performance of Services under this Agreement, whether by Service Provider, its employees, agents, consultants or sub-contractors.
Service Provider shall maintain records of the employee benefits provided to any employee of Service Provider performing Services
hereunder on a substantially full-time basis for a period of one (1) year or longer and such other information needed by CCT to
demonstrate compliance with the requirements of Internal Revenue Code Section 414(n) and related sub-sections, as amended from
time-to-time, pertaining to “leased employees”. For this purpose “on a substantially full-time basis” shall
mean fifteen hundred (1,500) hours in a twelve (12) month period or such amount specified by US tax regulation or notice in effect
during the term of this Agreement. Service Provider shall maintain such records for at least six (6) years and furnish such data
to CCT at its request.

 

14.    Notice

 

Any notice or other
communication required or permitted under this Agreement shall be in writing and shall be made by overnight courier or certified
mail, return receipt requested, and will be deemed given as of the date it is received by the receiving party. Notice shall be
given to the parties at the address listed below:

 

If to Service Provider:

 

Enumeral Biomedical Corporation

1450 Broadway, 24th Floor

New York, NY 10018

Attention: Arthur Tinkelenberg

 

If to CCT:

 

Celgene Cellular Therapeutics

33 Technology Drive,
2nd Floor

Warren, NJ 07059

Attention: *

 

With a copy to:

 

Vice President, Legal
and Chief Counsel

Celgene Corporation

86 Morris Avenue

Summit, NJ 07901

Fax: (908) 673-2771

 

		15.	Miscellaneous Provisions

 

		15.1	Assignability

 

No assignment by Service
Provider of this Agreement or any of its rights, duties or obligations hereunder, shall be effective without CCT’s prior
written consent, and any attempted assignment in violation of this paragraph 16.1 shall be void.

 

		15.2	Relief

 

In the event of the
actual or threatened breach by Service Provider of any of the terms of paragraphs 3 or 4 hereof, CCT shall have the right to specific
performance and injunctive relief. The rights granted by this paragraph are in addition to all other remedies and rights available
at law or in equity.

 

		15.3	Complete Agreement

 

This Agreement, together
with any Exhibit(s) attached hereto, constitutes the entire agreement between the parties hereto with respect to the subject matter
hereof, and there are no other agreements or understandings, written or oral, between the parties relating to the subject matter
of this Agreement.

 

		15.4	Amendments

 

This Agreement may
not be altered, changed or amended except by a writing signed by each of the parties hereto.

 

		15.5	Survival

 

The provisions of paragraphs
3, 4, 8, 9, 10, 11, 12, 13, 15.9 and 15.10 of this Agreement shall survive the expiration and/or termination of this Agreement.

 

		15.6	Severability

 

In the event that any
provision of this Agreement is held illegal or invalid for any reason, such provision shall not affect the remaining parts of this
Agreement, but this Agreement shall be construed and enforced as if that legal and invalid provision had never been inserted herein.

 

    	Enumeral Biomedical CCT MSPA 2.17.12 rao (28651)	6

    	 

    

 

		15.7	Captions and Headings

 

The captions and headings
in this Agreement are for convenience and reference only, and they shall in no way be held to explain, modify, or construe the
meaning of the terms of this Agreement.

 

		15.8	Counterpart Originals

 

This Agreement may
be executed in multiple counterparts, each of which, when executed shall be deemed to be an original and all of which together
shall constitute one and the same document.

 

		15.9	Governing Law; Jurisdiction

 

This Agreement shall
be governed by, and construed in accordance with, the laws of the State of New Jersey without giving effect to the choice of law
principles thereof. The parties hereby consent to the jurisdiction of the state and federal courts sitting in the State of New
Jersey, and any Courts of Appeal therefrom, in connection with any dispute arising in connection with this Agreement or the provision
by Service Provider of Services hereunder.

 

		15.10	Use of Name.

 

Both parties agree
that it will not use the name, logos, marks or trade names of the other party (or its affiliates), including, without limitation,
in any press release or public announcement, or in the promotion of any product or service without the prior written consent of
such party’s Investor Relations department. The obligations in this section shall survive expiration or termination of the
Agreement.

  

THIS AGREEMENT WILL NOT BE CONSIDERED
ACCEPTED, APPROVED, OR OTHERWISE EFFECTIVE UNTIL THE SIGNATURE OF EACH PARTY IS AFFIXED IN THE SPACE PROVIDED BELOW. PLEASE BE
ADVISED THAT A FULLY EXECUTED AGREEMENT MUST BE RETURNED TO AND RECEIVED BY CCT WITHIN 60 DAYS OF THE GENERATION OF THE CONTRACT.
IF NOT RECEIVED WITHIN THAT PERIOD, CCT RESERVES THE RIGHT TO RE-EVALUATE THE TERMS AND CONDITIONS OF THE AGREEMENT, INCLUDING
HOLDING THE AGREEMENT NULL AND VOID.

 

IN WITNESS WHEREOF,
the parties hereto have caused their duly authorized representatives to sign this Agreement upon the date first set forth above.

 

	ENUMERAL BIOMEDICAL CORPORATION	CELGENE CELLULAR THERAPEUTICS
	 	 
	By: /s/ Arthur Tinkelenberg	By: /s/ George Matcham (Signature)
	 	 
	Name: Arthur Tinkelenberg, PhD	Name: George Matcham (Print)
	 	 
	Title: Chief Executive Officer	Title: COO & SVP
	 	 
	Date: March 14th 2012	Date: 3-27-12
	 	 
	 	Approved for Legal Content: 3/22/2012

    	Enumeral Biomedical CCT MSPA 2.17.12 rao (28651)	7

    	 

    

 

WORK ORDER Nr. 1

 

Work Order for assay assessment for *

 

Celgene Corporation and Service Provider have entered into a
Master Service Provider Agreement dated March 14, 2012 (the “Agreement”) which provides that a Work Order be entered
into to set out with specificity the details of a particular study and Services. The terms contained herein are pursuant to and
governed by such Agreement.

 

This Work Order is effective as of October 29th,
2012, and shall terminate as of December 31st, 2013, and is by and between Celgene Cellular Therapeutics (a whole owned
subsidiary of Celgene Corporation) with its address located at 33 Technology Drive, 2nd Floor, Warren, NJ 07059 (hereinafter
“CCT”) and Enumeral Biomedical Corporation, with its address located at 1450 Broadway, 24th Floor, New York,
NY 10018 (hereinafter “Service Provider”).

 

		I.	Description of Services:

 

This Work Order has been generated based
on the assumptions listed below:

·       Deliverable
1 – An assay using Service Provider’s technology will be designed that will encompass *. Deliverable 1 will be considered
completed upon CCT’s review and approval from data of applying the assay to *.

·       Deliverable
2 – After feedback from CCT, the assay will be optimized in order to be applied to *. Deliverable 2 will be considered completed
upon CCT’s review and approval of the data from applying the newly-optimized assay to *.

·       Deliverable
3 – Data comprising * and * from * and acceptable controls will be delivered to CCT. Deliverable 3 will be considered completed
upon delivery and approval of data from CCT.

 

		II.	Key Personnel

 

Derek Brand has been identified as Key
Personnel, according to the terms of the Agreement.

 

		III.	Payment Schedule

 

Service Provider will invoice Celgene for
all services completed for the budget category for which a trigger has been achieved:

 

	Milestone	 	Payment Amount	 
	Initiation of project	 	$	40,000.00	 
	Review and Approval of data from Deliverable No. 1	 	 	*	 
	Review and Approval of data from Deliverable No. 2	 	 	*	 
	Completion of project (Deliverable 3)	 	 	*	 
	Total	 	 	*	 

 

		·	*, and affiliated reagents totaling an estimated *.

 

    	Enumeral Biomedical Corp_Exhibit 1 to MSA_*_Final_v19October12ss_#30978 
CONFIDENTIAL	Page 1 of 3

    	 

    

 

Professional Costs:

 

Total professional costs for the services
shall not exceed * and will be paid according to the following schedule, unless otherwise agreed. A final reconciliation of budget
line items and services completed will be performed prior to submitting the final invoice. Such reconciliation will be evidenced
in a Change Order, if required and reflected in the final invoice.

 

Pass-Through Costs

 

Total pass-through costs for the services
shall not exceed * unless otherwise agreed to by both parties and shall be invoiced and reimbursed on a monthly basis.

 

Invoices must reference the purchase order
(PO) number and are to be sent to the attention of:

 

Celgene Corporation

Attn: Accounts Payable

P.O. Box 1007

Summit, NJ 07902-1007

Referencing: *

 

Celgene shall pay the amount of each invoice
received from Service Provider within forty-five (45) days of receipt by Celgene, unless Celgene has notified Service Provider
within such forty-five (45) day period that it disputes any particular invoiced item(s), which dispute the parties shall attempt
in good faith to resolve.

 

Because of the difficulty in substantiating
the validity of claims for payment increases with time, Celgene reserves the right to decline to pay for expenses that are invoiced
more than ninety (90) days after an expense has been incurred. In no event will Celgene pay on invoices submitted more than one
hundred eighty (180) days after an expense has been incurred.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK – SIGNATURE
PAGE FOLLOWS]

 

    	Enumeral Biomedical Corp_Exhibit 1 to MSA_*_Final_v19October12ss_#30978 
CONFIDENTIAL	Page 2 of 3

    	 

    

 

IN WITNESS WHEREOF, the parties have executed this Work Order
the day and year set forth above.

 

	Enumeral Biomedical Corporation	 	Celgene Corporation
	 	 	 	 
	By: /s/ Arthur H. Tinkelenberg	 	By: 	Please see attached
	 	 	 	 
	Title:  Arthur H. Tinkelenberg, President & CEO	 	Title: 	 
	 	 	 	 
	Date:  10/19/2012	 	Date: 	 

 

    	Enumeral Biomedical Corp_Exhibit 1 to MSA_*_Final_v19October12ss_#30978 
CONFIDENTIAL	Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]